Mabwell (迈威生物) A+H IPO Trading
Mabwell A+H is set to start trading on April 28. We update deal dynamics, recap valuation, and reference peers. We think the deal will be...
187 Views
Mabwell (Shanghai) Bioscience IPO: Aiming for Next Level of Growth Riding on ADC Pipeline
Mabwell seeks to raise ~$185M via HK IPO, which consists of 47M H shares. Offer price range is HK$27.64–30.71 per share. Subscriptions will close...
220 Views
Mabwell (迈威生物) A+H: Moderate Upside but Connect Event Ahead
Mabwell A+H: China biotech IPO with a near-term Phase III catalyst, but both lead indications face meaningful competitive headwinds. Moderate...
245 Views
Pre-IPO Mabwell (Shanghai) Bioscience (PHIP Updates) - Some Points Worth the Attention
Mabwell's commercialization progress is significantly below expectations. If future external cooperation weakens, revenue scale will shrink...
176 Views
Primer: Mabwell (Shanghai) Bioscience (MAB HK) - Apr 2026
Mabwell is an innovation-driven biopharmaceutical company transitioning from a research and development focus to a commercial-stage entity with...
140 Views